Redox-sensitive dimeric camptothecin phosphatidylcholines-based liposomes for improved anticancer efficacy

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Camptothecin (CPT) is a potent anticancer drug with limited clinical use due to toxicity.
• Developing targeted drug delivery systems can improve CPT's therapeutic index.
• Redox-sensitive systems offer potential for controlled drug release in tumor microenvironments.

Purpose of the Study:

• To develop and evaluate a redox-triggered liposomal system for camptothecin delivery.
• To synthesize and characterize camptothecin-phosphorylcholine conjugates (CPT-SS-GPCs).
• To assess the in vitro and in vivo anticancer efficacy of the developed liposomes.

Main Methods:

• Synthesis of CPT-phosphorylcholine conjugates (CPT-SS-GPCs) using a disulfide linker.
• Assembly of CPT-SS-GPCs into liposomes with controlled size (150-200 nm).
• In vitro and in vivo studies to evaluate drug release, cellular uptake, and anticancer activity.

Main Results:

• CPT-SS-GPC liposomes demonstrated high drug loading and uniform particle size.
• Rapid release of parent CPT was observed under reductive conditions.
• Enhanced cellular uptake and significant in vitro and in vivo anticancer efficacy were achieved.

Conclusions:

• Redox-triggered CPT-SS-GPC liposomes represent a promising strategy for improved tumor therapy.
• The developed system enhances CPT's clinical potential through targeted delivery and controlled release.
• This approach holds significant promise for advancing cancer treatment.